When the unexpected strikes: hepatocellular carcinoma in a teen with ataxia-telangiectasia.
[BACKGROUND] Ataxia-telangiectasia (A-T) is a rare autosomal recessive disorder characterized by progressive cerebellar ataxia, oculocutaneous telangiectasia, and profound immunodeficiency.
APA
Alesaeidi S, Alavi S, et al. (2025). When the unexpected strikes: hepatocellular carcinoma in a teen with ataxia-telangiectasia.. Oxford medical case reports, 2025(11), omaf237. https://doi.org/10.1093/omcr/omaf237
MLA
Alesaeidi S, et al.. "When the unexpected strikes: hepatocellular carcinoma in a teen with ataxia-telangiectasia.." Oxford medical case reports, vol. 2025, no. 11, 2025, pp. omaf237.
PMID
41311449
Abstract
[BACKGROUND] Ataxia-telangiectasia (A-T) is a rare autosomal recessive disorder characterized by progressive cerebellar ataxia, oculocutaneous telangiectasia, and profound immunodeficiency. Although individuals with A-T exhibit a heightened predisposition to malignancies, the incidence of hepatocellular carcinoma is exceptionally rare where diagnosis may be further complicated by the underlying immunodeficiency.
[CASE PRESENTATION] We present a 14-year-old male with a confirmed diagnosis of A-T since the age of two, experiencing progressive neurological decline. Hepatocellular carcinoma was identified during routine systemic surveillance through imaging studies and rising alpha-fetoprotein levels. The patient underwent chemotherapy with PLADO regimen and sorafenib, alongside monthly intravenous immunoglobulin. He had an exceptionally satisfactory course and successful outcome following chemotherapy.
[CONCLUSION] The coexistence of A-T and hepatocellular carcinoma is an exceptionally rare phenomenon, with only a limited number of cases reported globally. Comprehensive, multidisciplinary management is crucial in optimizing survival outcomes and enhancing the quality of life in these medically complex patients.
[CASE PRESENTATION] We present a 14-year-old male with a confirmed diagnosis of A-T since the age of two, experiencing progressive neurological decline. Hepatocellular carcinoma was identified during routine systemic surveillance through imaging studies and rising alpha-fetoprotein levels. The patient underwent chemotherapy with PLADO regimen and sorafenib, alongside monthly intravenous immunoglobulin. He had an exceptionally satisfactory course and successful outcome following chemotherapy.
[CONCLUSION] The coexistence of A-T and hepatocellular carcinoma is an exceptionally rare phenomenon, with only a limited number of cases reported globally. Comprehensive, multidisciplinary management is crucial in optimizing survival outcomes and enhancing the quality of life in these medically complex patients.